Interestingly, for CLL/SLL [92] and Burkitt lymphoma [93], NLRP3 inflammasome activation acts as a tumor-suppressive factor, while for CTCLs, NLRP3 inflammasome activation was associated with both pro- and anti-tumorigenic effects [120,124]. Here, NLRP3 is linked to B-cell chronic lymphocytic leukemia.